Disc Medicine prices $450M primary offering at $75/share; net proceeds $422.4M to fund bitopertin commercialization

Filed October 21, 2026 · ~1 min read

Key Changes

• high

  Disc Medicine is offering 6,000,000 shares at $75.00 per share, raising $450M gross; net proceeds to the company are $422.4M.

  The Offering verify on EDGAR →
• high

  Proceeds will fund R&D, bitopertin commercialization for EPP and XLP, and general corporate purposes, extending cash runway into 2030.

  Use of Proceeds verify on EDGAR →
• high

  New investors face immediate dilution of $50.95 per share, as net tangible book value rises to only $24.05 after the offering.

  Dilution verify on EDGAR →